Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ESI-05 (NSC-116966) is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
2 mg | 在庫あり | ¥ 7,500 | |||
5 mg | 在庫あり | ¥ 12,000 | |||
10 mg | 在庫あり | ¥ 21,500 | |||
25 mg | 在庫あり | ¥ 39,000 | |||
50 mg | 在庫あり | ¥ 65,500 | |||
100 mg | 在庫あり | ¥ 112,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 13,500 |
説明 | ESI-05 (NSC-116966) is a specific EPAC2 (exchange protein directly activated by cAMP 2) antagonist (IC50: 0.4 μM). ESI-05 inhibits cAMP-mediated activation of EPAC2, as well as EAPC2, mediated Rap1 activation. |
ターゲット&IC50 | EPAC2:0.4 μM |
別名 | NSC 116966 |
分子量 | 274.38 |
分子式 | C16H18O2S |
CAS No. | 5184-64-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (303.70 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ESI-05 5184-64-5 GPCR/G Protein cAMP Diacylglycerol acyltransferase diabetes Inhibitor inhibit NSC 116966 Intracranial hemorrhage (ICH) Acyltransferase acyl-CoA:cholesterol acyltransferase insulin secretion mono- acylglycerol acyltransferase NSC-116966 exchange proteins directly activated by cAMP 2 (EPAC2) neurological disorders NSC116966 ESI 05 ESI05 GEF Diglyceride acyltransferase inhibitor